Marengo Therapeutics, Inc., a US-based company involved in novel therapeutics targeting the T cell receptor (TCR) V-beta to selectively activate the right T cell subsets to fight cancer, announced on Friday that it has dosed its first subject in its ongoing clinical trial of STAR0602 (START-001).
The company's START-001 trial, a seamless Phase one/two clinical trial, is to assess the safety and clinical activity of STAR0602 as monotherapy in a biomarker-enriched cohort of patients with PD-1 refractory advanced solid tumours.
Presently, the trial is enrolling subjects at two top US cancer research institutes, National Institutes of Health (NIH)'s National Cancer Institute (NCI) and Mass General Hospital (MGH)/Harvard Medical School, co-led by seasoned clinical and translational researchers James Gulley, MD, PhD, of NCI and Ryan Sullivan, MD, of MGH. The company is planning to add more top cancer centres to support the further expansion of the study.
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
TransCode Therapeutics announces reverse stock split
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
TransCode Therapeutics reports progress in metastatic cancer trial
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
AllyGPO and BioCareSD advance community oncology through integrated, tech-driven drug management
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
Atossa Therapeutics secures new US patent for proprietary (Z)-endoxifen formulations
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder